International Transplantation Science (ITS) Meeting

It is our announce to present the 3rd International Transplantation Science (ITS) Meeting, jointly organised by The Transplantation Society (TTS), the American Society of Transplantation (AST), and the European Society for Organ Transplantation (ESOT).
ITS 2023 will be held in Niagara-on-the-Lake, Ontario, Canada from April 30th to May 3rd, 2023. The meeting is intended to stimulate in-depth, cutting-edge discussions from leading experts addressing challenges that arise from connecting basic fundamental to translational science in transplantation.

Submit your abstract by December 20, 2022!

Transplantation Science Symposium (TSS) Asian Regional Meeting 2022

Cutting-Edge Transplant Research -Bench to Bedside-
November 25-26, 2022 - Kyoto, Japan

TTS Vice President Stefan G. Tullius will be giving a keynote lecture on "Emerging Topics in Organ Transplantation: Addressing the Organ Shortage Crisis and Refining Immunosuppression"
TTS Women in Transplantation will be hosting a session on November 26 on "Gender Disparity in Kidney Transplantation in Asia". The session will be chaired by TTS Councilor Curie Ahn (Korea) and Yuki Nakagawa (Japan). The speakers include Maggie Kam Man Ma (Hong Kong), Yuki Nakagawa (Japan), Germaine Wong (Australia) and Miyeun Han (Korea).

Transplantation Updates

Transplantation - Highlighted Articles

Humoral and Cellular Response of Transplant Recipients to a Third Dose of mRNA SARS-CoV-2 Vaccine: A Systematic Review and Meta-analysis

High rates of nonresponse to 2 doses of mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine have been reported in transplant recipients. Several studies have investigated the efficacy of a third dose in this population. However, efficacy remains unclear, as response rates vary across studies. Therefore, we conducted a systematic review and meta-analysis to determine the efficacy of a third dose of any mRNA SARS-CoV-2 vaccine in transplant recipients.

Predicting a Positive Antibody Response After 2 SARS-CoV-2 mRNA Vaccines in Transplant Recipients: A Machine Learning Approach With External Validation

olid organ transplant recipients (SOTRs) are less likely to mount an antibody response to SARS-CoV-2 mRNA vaccines. Understanding risk factors for impaired vaccine response can guide strategies for antibody testing and additional vaccine dose recommendations.

Transplantation - Week's Most Downloaded Paper

Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group

With the development of modern solid-phase assays to detect anti-HLA antibodies and a more precise histological classification, the diagnosis of antibody-mediated rejection (AMR) has become more common and is a major cause of kidney graft loss. Currently, there are no approved therapies and treatment guidelines are based on low-level evidence. The number of prospective randomized trials for the treatment of AMR is small, and the lack of an accepted common standard for care has been an impediment to the development of new therapies. To help alleviate this, The Transplantation Society convened a meeting of international experts to develop a consensus as to what is appropriate treatment for active and chronic active AMR.

Transplantation Direct - Highlighted Tweet

Determining Clinical Thresholds for Donor HLA Eplet Compatibility to Predict Best Outcomes Following Lung Transplantation

Currently, the assessment of immunological risk in lung transplantation (LTx) does not completely consider HLA compatibility at the molecular level. We have previously demonstrated the association of HLA eplets in predicting chronic lung allograft dysfunction following LTx; however, the associations between HLA eplet mismatch (epMM) loads and overall survival are unknown.

TTS-ILTS Paired Transplant Centers Program - Apply Today!

Program Schedule

Deadline to Apply: January 1, 2023
Program Start Date: April 1, 2023

An experienced supporting transplant center (SC) in the developed world is paired with an emerging transplant center (EC) to facilitate vital multidisciplinary training and an exchange of knowledge and expertise.
The project aims to benefit both centers. The SC is involvedin global health, and promotes ethical and competent transplantation in regions of the world with limited or no current access to transplantation. The EC connects with a multidisciplinary team of experts in transplantation from a world-leading center.
The ultimate goal is for Level 3 centers to graduate and become true local centers of excellence for regional training and support.
The TTS-ILTS Paired Transplant Centers Program is bound by a limited budget which it cannot exceed. This budget is divided over all center pairs who receive a different financial allocation dependent on their level within the program.
  • Level 1 - maximum annual allocation per pair: $ 3,500 USD
  • Level 2 - maximum annual allocation per pair: $12,000 USD
  • Level 3 - maximum annual allocation per pair: $15,000 USD
Programs Launched in April 2022
Dow Universtiy Hospital, Karachi, Pakistan paired with the University of Chicago, Chicago, USA

TTS and ILTS congratulates these teams and wishes them every success in their collaborations over the next six years and beyond.

In the News 



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6